Introduction: Exeter-based university spin-out Senisca Ltd has raised £3.7m in seed funding, in addition to £1.1m in non-dilutive funding, to advance its pipeline of drugs targeting RNA splicing dysregulation.
Main points:
1. The funding will support the preclinical development of Senisca’s senotherapeutic programs, which aim to target the causes of age-related diseases through RNA splicing regulation.
2. Senisca has raised a total of £7.1 million in investor capital and an additional £1.1 million in non-dilutive funding and commercial revenue.
3. The company harnesses RNA biology, specifically oligonucleotide therapeutics, to rejuvenate senescent cells by modifying their pro-inflammatory RNA isoform profile and function.
4. The initial programs of the company focus on RNA splicing dysregulation in various pharmacological and skin health indications.
5. German researchers have also identified RNA polymerase I blockers as potential anti-aging medicines, which decrease oxidative phosphorylation and the production of reactive oxygen species.
Conclusion:
Senisca Ltd has secured £3.7m in seed funding, bringing its total investor capital to £7.1m. The funding will support the preclinical development of the company’s senotherapeutic programs targeting age-related diseases through RNA splicing regulation. The company’s approach harnesses RNA biology to modify the function of senescent cells, and initial programs focus on RNA splicing dysregulation. This funding further validates Senisca’s scientific approach and potential in the field of aging research.
